Romain Breguet1,2, Sana Boudabbous1, Lawrence F Pupulim1, Christoph D Becker1,2, Laura Rubbia-Brandt2,3, Christian Toso2,4, Maxime Ronot1,5, Sylvain Terraz6,7. 1. Department of Radiology, University Hospitals of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland. 2. Hepato-Pancreato-Biliary Centre, University Hospitals of Geneva, Geneva, Switzerland. 3. Department of Clinical Pathology, University Hospitals of Geneva, Geneva, Switzerland. 4. Department of Visceral Surgery, University Hospitals of Geneva, Geneva, Switzerland. 5. Department of Radiology, University Hospitals of Beaujon, Paris, France. 6. Department of Radiology, University Hospitals of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland. sylvain.terraz@hcuge.ch. 7. Hepato-Pancreato-Biliary Centre, University Hospitals of Geneva, Geneva, Switzerland. sylvain.terraz@hcuge.ch.
Abstract
OBJECTIVES: To evaluate the safety and efficacy of ethylene vinyl alcohol copolymer (EVOH) injection for selective occlusion of portal branches considered at risk for non-target embolisation during preoperative portal vein embolisation (PVE). METHODS: Twenty-nine patients (mean age, 57 ± 17 years) submitted to PVE with n-butyl-cyanoacrylate (NBCA) and additional EVOH for selected portal branches were retrospectively analysed. Indications for the use of EVOH and the selected portal branches were evaluated. Degree of hypertrophy of the future liver remnant (FLR) and kinetic growth were assessed by CT volumetry performed before and 3-6 weeks after PVE. Clinical outcome and histopathological analysis of portal veins occluded with EVOH were reviewed. RESULTS: EVOH was indicated intraoperatively for embolisation of selected portal branches that the operator reported at risk to provoke non-target embolisation with NBCA. Indications for the use of EVOH were embolisation of segment IV (n = 21), embolisation of segmental portal branches with early bifurcation (n = 7) and PVE in a 1-year-old girl with cystic hamartomas. All targeted portal branches were successfully embolised. There were no cases with non-target embolisation by EVOH. The degree of hypertrophy of the FLR was 14.3 ± 8.1% and the kinetic growth rate was 2.7 ± 1.8% per week. CONCLUSION: EVOH is safe and effective for embolisation of selected portal vein branches considered at risk for non-target embolisation. KEY POINTS: • EVOH is another effective liquid embolic agent for preoperative PVE. • EVOH is relatively simple to handle with a minimal risk of non-target embolisation. • During PVE, some portal branches considered complicated to occlude with NBCA may be efficiently embolised with EVOH.
OBJECTIVES: To evaluate the safety and efficacy of ethylene vinyl alcohol copolymer (EVOH) injection for selective occlusion of portal branches considered at risk for non-target embolisation during preoperative portal vein embolisation (PVE). METHODS: Twenty-nine patients (mean age, 57 ± 17 years) submitted to PVE with n-butyl-cyanoacrylate (NBCA) and additional EVOH for selected portal branches were retrospectively analysed. Indications for the use of EVOH and the selected portal branches were evaluated. Degree of hypertrophy of the future liver remnant (FLR) and kinetic growth were assessed by CT volumetry performed before and 3-6 weeks after PVE. Clinical outcome and histopathological analysis of portal veins occluded with EVOH were reviewed. RESULTS:EVOH was indicated intraoperatively for embolisation of selected portal branches that the operator reported at risk to provoke non-target embolisation with NBCA. Indications for the use of EVOH were embolisation of segment IV (n = 21), embolisation of segmental portal branches with early bifurcation (n = 7) and PVE in a 1-year-old girl with cystic hamartomas. All targeted portal branches were successfully embolised. There were no cases with non-target embolisation by EVOH. The degree of hypertrophy of the FLR was 14.3 ± 8.1% and the kinetic growth rate was 2.7 ± 1.8% per week. CONCLUSION:EVOH is safe and effective for embolisation of selected portal vein branches considered at risk for non-target embolisation. KEY POINTS: • EVOH is another effective liquid embolic agent for preoperative PVE. • EVOH is relatively simple to handle with a minimal risk of non-target embolisation. • During PVE, some portal branches considered complicated to occlude with NBCA may be efficiently embolised with EVOH.
Authors: Lorenzo Capussotti; Andrea Muratore; Alessandro Ferrero; Giovanni Carlo Anselmetti; Andrea Corgnier; Daniele Regge Journal: Arch Surg Date: 2005-11
Authors: Sylvain Terraz; Maxime Ronot; Romain Breguet; Mehrak Anooshiravani; Laura Rubbia-Brandt; Christoph D Becker; Barbara E Wildhaber Journal: Pediatrics Date: 2015-09-21 Impact factor: 7.124
Authors: Nuh N Rahbari; O James Garden; Robert Padbury; Mark Brooke-Smith; Michael Crawford; Rene Adam; Moritz Koch; Masatoshi Makuuchi; Ronald P Dematteo; Christopher Christophi; Simon Banting; Val Usatoff; Masato Nagino; Guy Maddern; Thomas J Hugh; Jean-Nicolas Vauthey; Paul Greig; Myrddin Rees; Yukihiro Yokoyama; Sheung Tat Fan; Yuji Nimura; Joan Figueras; Lorenzo Capussotti; Markus W Büchler; Jürgen Weitz Journal: Surgery Date: 2011-01-14 Impact factor: 3.982
Authors: Maarten L J Smits; Peter Vanlangenhove; Emiel J C Sturm; Maurice A A J van den Bosch; Monirath Hav; Marleen Praet; Maarten A D Vente; Frédéric R Snaps; Luc Defreyne Journal: Cardiovasc Intervent Radiol Date: 2011-10-07 Impact factor: 2.740
Authors: T de Baere; J M Robinson; F Deschamps; P Rao; C Teriitheau; D Goere; D Elias Journal: Cardiovasc Intervent Radiol Date: 2010-01-08 Impact factor: 2.740
Authors: Sébastien Gautier; Olivier Chevallier; Charles Mastier; Philippe d'Athis; Nicolas Falvo; Frank Pilleul; Marco Midulla; Patrick Rat; Olivier Facy; Romaric Loffroy Journal: Quant Imaging Med Surg Date: 2021-02
Authors: Long R Jiao; Ana B Fajardo Puerta; Tamara M H Gall; Mikael H Sodergren; Adam E Frampton; Tim Pencavel; Myura Nagendran; Nagy A Habib; Ara Darzi; Madhava Pai; Rob Thomas; Paul Tait Journal: Cancers (Basel) Date: 2019-03-04 Impact factor: 6.639
Authors: Massimo Venturini; Luigi Augello; Carolina Lanza; Marco Curti; Andrea Coppola; Filippo Piacentino; Francesco De Cobelli Journal: Eur Radiol Exp Date: 2020-12-10